Company Insights

ONMD customer relationships

ONMD customer relationship map

OneMedNet (ONMD): Customer Relationships That Drive Its Transition to iRWD Revenue

OneMedNet operates a two-pronged business: it sells regulatory‑grade imaging and clinical data (iRWD™) on a fixed‑fee, usage-based basis and historically operated a subscription imaging exchange (BEAM) that the company is winding down. Revenues today increasingly come from multi‑year iRWD contracts that supply de‑identified imaging and contextual clinical records to AI developers, device makers and life‑sciences customers; BEAM subscription revenue is being reduced as the firm focuses on higher‑margin data services. If you are evaluating ONMD as an investment, prioritize the iRWD customer pipeline, contractual terms (usage vs. subscription), and concentration risk.
Learn more at our homepage: https://nullexposure.com/

How to read the customer signals: what the contracts and disclosures tell investors

OneMedNet’s disclosures and media coverage reveal a clear operating posture:

  • Contracting posture: The company sells iRWD on a fixed fee, per‑data‑unit basis with revenue recognized on delivery, and it historically recognized BEAM as ratable subscription revenue invoiced quarterly or annually. This mix creates a shift from recurring subscription economics toward transactional, delivery‑tied revenue as iRWD volumes scale.

  • Concentration and materiality: OneMedNet reported that two customers represented 35% and 17% of 2024 revenue, a 52% aggregate concentration. Customer concentration is a material company‑level risk—loss or non‑renewal of a major account would materially affect near‑term results.

  • Geographic footprint and addressability: The company markets itself as a global provider of imaging RWD and reports discrete revenue in Europe & Middle East (EMEA) as well as the Americas, signaling cross‑border demand for regulatory‑grade imaging assets.

  • Relationship maturity and strategic shift: Management has stopped renewals for most BEAM customers as BEAM is being discontinued, while iRWD deliveries and web imaging revenue are declared active and growing—this is a deliberate product rationalization toward services that support AI and regulatory use cases.

  • Role in the value chain: OneMedNet functions primarily as a seller of curated clinical imaging and contextual records to customers building AI, medical device and clinical evidence solutions, while its former BEAM platform positioned it as a marketplace operator. These are company-level signals drawn from public excerpts.

Customer relationships: who they are and what they bought

mlHealth 360 — a commercial partner for AI model validation

OneMedNet provided regulatory‑grade multimodal imaging and clinical data that supported mlHealth 360’s FDA 510(k) clearance for its Scaida BrainCT‑ICH product, and the companies signed a multi‑year iRWD subscription giving mlHealth continuous access to curated imaging and clinical records for model development and validation. This is a strategic, revenue‑generating relationship that directly validates OneMedNet’s product for regulatory use (news release, Jan–Feb 2026: https://www.barchart.com/story/news/37174028/onemednet-real-world-data-supports-fda-510k-clearance-of-ai-powered-scaida-brainct-ich-software and https://www.globenewswire.com/news-release/2026/02/12/3237273/0/en/OneMedNet-Reports-Record-2025-Bookings-of-2-79-Million-Surpassing-Prior-Year-by-More-Than-4-1X-and-Accelerating-Subscription-Transition.html).

Risorius Co., Ltd. — a licensing agreement to advance EEG and CNS research

OneMedNet entered a strategic data licensing agreement with Risorius to supply imaging and clinical records to support EEG‑based biomarker research and AI platforms for CNS indications, positioning OneMedNet as a data provider to neurotechnology innovators. The announcement highlights the company’s ability to license regulated, de‑identified clinical material for specialty research (company announcement, FY2026: https://www.quiverquant.com/news/OneMedNet+Corporation+Enters+Strategic+Data+Licensing+Agreement+with+Risorius+Co.%2C+Ltd.+to+Enhance+Neurotechnology+Research).

Circle CVI — a subscription conversion example in the pipeline

Circle CVI is named among the subscription agreements announced in 2025 as part of OneMedNet’s shift toward subscription‑style iRWD engagements, reflecting the company’s effort to convert customers into longer‑term data relationships. This customer is cited in the company’s 2025 bookings announcement as evidence of growing recurring iRWD bookings (press release, Feb 12, 2026: https://www.globenewswire.com/news-release/2026/02/12/3237273/0/en/Onemednet-Reports-Record-2025-Bookings-of-2-79-Million-Surpassing-Prior-Year-by-More-Than-4-1X-and-Accelerating-Subscription-Transition.html).

Xylexa — repeat business based on speed and regulatory standards

Xylexa’s Chief Strategy Officer publicly praised OneMedNet for rapid sourcing and regulatory‑grade curation of clinical imaging data and said the company remains a returning strategic partner, indicating repeat customer behavior and trust among AI and evidence‑generation buyers (RSNA 2025 commentary, Dec 2025: https://www.sahmcapital.com/news/content/onemednet-reports-strong-momentum-and-industry-excitement-at-rsna-2025-12-10).

What investors should infer from these customer ties

These relationships collectively demonstrate that OneMedNet is positioning iRWD as the primary revenue engine, selling high‑quality imaging and clinical records that customers use for regulatory submissions, AI model development and device validation. The mlHealth 360 FDA clearance is particularly significant: it serves as third‑party validation that OneMedNet’s outputs meet regulatory‑grade expectations and increases the commercial value of its iRWD offering.

At the same time, concentration risk is elevated—with two customers representing over half of reported revenue in 2024, investors must monitor renewal cadence and new contract wins. The shift from BEAM subscriptions (being wound down) to usage‑based iRWD deliveries increases near‑term revenue volatility but can expand gross margins if iRWD volumes scale and per‑unit economics improve. The company’s global footprint, including EMEA revenue, supports addressable market claims but also introduces cross‑border regulatory and compliance responsibilities.

Explore OneMedNet coverage and signals at https://nullexposure.com/ for investor workflows.

Risks, catalysts and what to watch next

  • Risks: customer concentration, delivery timing for fixed‑fee iRWD contracts, and the transitional revenue gap from BEAM discontinuation.
  • Catalysts: additional multi‑year iRWD contracts, more regulatory clearances supported by OneMedNet data, and successful geographic expansion into EMEA.
  • Operational signs to monitor: pace of iRWD deliveries, invoicing cadence and recognitions tied to per‑data‑unit contracts, and any new disclosures clarifying the revenue mix between usage‑based iRWD and recurring ARR.

Bottom line and recommended actions for investors

OneMedNet is evolving from a platform operator into a high‑value supplier of regulatory‑grade imaging and clinical records. That strategic pivot creates both upside (higher‑value customers, validated regulatory use) and near‑term revenue risk (concentration and transition from BEAM). Investors should focus on pipeline conversion, renewal behavior for the top two customers, and evidence of repeatable per‑unit economics for iRWD. For a consolidated view of customer signals and to track developments, visit our hub: https://nullexposure.com/

Key takeaway: iRWD adoption by AI and device customers—validated by FDA submissions—is the primary driver of ONMD’s valuation story; customer concentration and revenue transition are the principal risks to underwrite.